Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AAR

The Orkambi row explained

Q&A and timeline

- PMLiVE

Brexit causing ‘significant’ generic drug shortages

Generics firms contest reason for shortages

- PMLiVE

Amgen and UCB’s Evenity finally approved, but with label warnings

Drug unlikely to match Prolia's revenues

- PMLiVE

#OrkambiNow?

After a long standoff over CF treatment Orkambi, is a deal imminent?

- PMLiVE

Novartis and Amgen come to blows over migraine partnership

Amgen seeks to terminate contract

- PMLiVE

AVEO warns EU approval of Fotivda could be at risk

Concerns arose with overall survival data

- PMLiVE

Pharma asked to consider 5 things as no-deal Brexit looms again

Second round of MPs' indicative voting fails to produce majority

- PMLiVE

Call for temporary medicines export ban if no-deal Brexit strikes

NHS could struggle to source medicines

- PMLiVE

UK business: Brexit deadlock causing “frustration and anger”

Pharma must still plan for no-deal, only slightly later

- PMLiVE

Investments show UK biotech still booming despite Brexit

UK raised a quarter of all European biotech funds

- PMLiVE

Pharma fears “lack of focus” on no-deal Brexit preparations

As Brexit is delayed, pharma suggests new measures to avoid no-deal drugs shortages

- PMLiVE

Amgen, Servier heart failure drug clears trial hurdle

Drug could be a blockbuster - if it hits key endpoints

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links